Search
KDT-3594
go.drugbank.com/drugs/DB17085InvestigationalKDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
MD05
go.drugbank.com/drugs/DB06375InvestigationalMD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).
CERE-120
go.drugbank.com/drugs/DB05637InvestigationalCERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. … It was under investigation in clinical trials for the treatment of Parkinson's Disease.
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
Distigmine
go.drugbank.com/drugs/DB13694InvestigationalIt is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors. … Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide.
Anisomycin
go.drugbank.com/drugs/DB07374ExperimentalAnisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria _Streptomyces griseolus_. This drug acts to inhibit bacterial protein and DNA synthesis.
ZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalThe ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758]. … Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and tolerance[A219758,L16493].
Basal Cell Carcinoma (BCC)
go.drugbank.com/conditions/DBCOND0040396Drugs: Aminolevulinic acidSynonyms: (Basal cell carcinoma) or (Bowen's disease) or (rodent ulcer) or (skin Ca - excluding melanoma) or (Ca skin - other)MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.